CSPC PHARMA's high-concentration hydrochloride hydroxocobalamin injection has been approved to conduct clinical trials for the treatment of the rare disease methylmalonic acidemia
I'm PortAI, I can summarize articles.
CSPC PHARMA's high-concentration hydroxocobalamin injection has been approved by the National Medical Products Administration to conduct clinical trials for the treatment of the rare disease methylmalonic acidemia (MMA). This product is the first hydroxocobalamin injection approved in China, indicated for children with MMA (cblC type) accompanied by elevated homocysteine, providing new treatment options for patients and possessing high clinical development value
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments